Department of Chemical and Biomolecular Engineering, KAIST (Korea Advanced Institute of Science and Technology), Daejeon, Korea.
Bioprocess Biosyst Eng. 2011 May;34(4):419-31. doi: 10.1007/s00449-010-0485-8. Epub 2010 Dec 3.
We carried out the first simulation on multi-stage continuous high cell density culture (MSC-HCDC) to show that the MSC-HCDC can achieve batch/fed-batch product titer with much higher productivity to the fed-batch productivity using published fermentation kinetics of lactic acid, penicillin and ethanol. The system under consideration consists of n-serially connected continuous stirred-tank reactors (CSTRs) with either hollow fiber cell recycling or cell immobilization for high cell-density culture. In each CSTR substrate supply and product removal are possible. Penicillin production is severely limited by glucose metabolite repression that requires multi-CSTR glucose feeding. An 8-stage C-HCDC lactic acid fermentation resulted in 212.9 g/L of titer and 10.6 g/L/h of productivity, corresponding to 101 and 429% of the comparable lactic acid fed-batch, respectively. The penicillin production model predicted 149% (0.085 g/L/h) of productivity in 8-stage C-HCDC with 40 g/L of cell density and 289% of productivity (0.165 g/L/h) in 7-stage C-HCDC with 60 g/L of cell density compared with referring batch cultivations. A 2-stage C-HCDC ethanol experimental run showed 107% titer and 257% productivity of the batch system having 88.8 g/L of titer and 3.7 g/L/h of productivity. MSC-HCDC can give much higher productivity than batch/fed-batch system, and yield a several percentage higher titer as well. The productivity ratio of MSC-HCDC over batch/fed-batch system is given as a multiplication of system dilution rate of MSC-HCDC and cycle time of batch/fed-batch system. We suggest MSC-HCDC as a new production platform for various fermentation products including monoclonal antibody.
我们进行了首次多阶段连续高密度细胞培养 (MSC-HCDC) 模拟,以证明 MSC-HCDC 可以使用已发表的乳酸、青霉素和乙醇发酵动力学达到批次/补料分批产物滴度,其生产力比补料分批生产力高得多。所考虑的系统由 n 个串联的连续搅拌釜式反应器 (CSTR) 组成,这些 CSTR 可以使用中空纤维细胞回收或细胞固定化进行高密度细胞培养。在每个 CSTR 中,都可以进行基质供应和产物去除。青霉素的生产受到葡萄糖代谢物抑制的严重限制,这需要多 CSTR 葡萄糖补料。8 阶段 C-HCDC 乳酸发酵产生了 212.9 g/L 的滴度和 10.6 g/L/h 的生产力,分别相当于可比乳酸补料分批的 101%和 429%。青霉素生产模型预测,在 40 g/L 细胞密度的 8 阶段 C-HCDC 中,生产力为 149%(0.085 g/L/h),在 60 g/L 细胞密度的 7 阶段 C-HCDC 中,生产力为 289%(0.165 g/L/h),与参考批次培养相比。2 阶段 C-HCDC 乙醇实验运行显示,在具有 88.8 g/L 滴度和 3.7 g/L/h 生产力的批次系统中,产物的滴度和生产力分别提高了 107%和 257%。MSC-HCDC 可以提供比批次/补料分批系统更高的生产力,并且也可以提高几个百分点的滴度。MSC-HCDC 相对于批次/补料分批系统的生产力比为 MSC-HCDC 的系统稀释率与批次/补料分批系统的循环时间的乘积。我们建议将 MSC-HCDC 作为各种发酵产物(包括单克隆抗体)的新生产平台。